A GMP self-inspection should reveal how reliably the pharmaceutical quality system works during normal operations. It should not be treated merely as preparation for an approaching regulatory inspection or as an exercise in completing a checklist.
A strong self-inspection examines what people actually do, compares it with approved requirements, verifies the supporting evidence and identifies weaknesses before they affect product quality or patient safety.
EU GMP Chapter 9 requires self-inspections to monitor GMP implementation and compliance and to propose necessary corrective measures. It also expects them to follow a prearranged programme, be conducted independently and in detail by competent personnel, and be recorded together with subsequent actions.
The real value, however, comes from how these requirements are applied in daily operations.
What is a GMP self-inspection?
A GMP self-inspection is a planned, documented and independent examination of selected operations and quality systems within a pharmaceutical facility. Its purposes are to determine whether:
- Approved procedures comply with applicable GMP requirements.
- Employees understand and consistently follow those procedures.
- Facilities, utilities and equipment remain suitable and controlled.
- Records provide complete, accurate and contemporaneous evidence.
- Deviations, complaints, failures and adverse trends are detected and addressed.
- Previous corrective and preventive actions remain effective.
- The pharmaceutical quality system is capable of protecting product quality and patients.
A self-inspection is not simply a tour of the facility. It combines observation, interviews, document review, record sampling and process tracing.
Self-inspection is different from routine supervision
Supervisors monitor daily work and address immediate operational concerns. A self-inspection takes a broader and more independent view. It asks questions such as:
- Does the approved system adequately control the risk?
- Is actual practice consistent with the written procedure?
- Do records support what employees say is happening?
- Are recurring problems being identified and escalated?
- Did previous corrective actions eliminate the underlying cause?
- Could the observed weakness affect other departments, products or batches?
The inspection must therefore look beyond isolated errors and evaluate the effectiveness of the system behind them.
1. Establish a risk-based inspection programme
The site should maintain an approved self-inspection programme covering the relevant elements of the pharmaceutical quality system. Typical areas include:
- Personnel, responsibilities and training
- Premises, utilities, equipment, calibration and maintenance
- Warehousing and material management
- Production and packaging operations
- Documentation and data integrity
- Quality control laboratories
- Qualification, validation and cleaning controls
- Deviations, investigations, CAPA and change control
- Complaints, returns and recalls
- Supplier, contractor, distribution and transport controls
- Product quality review and previous self-inspection commitments
Not every area needs the same attention at the same frequency. The programme should consider patient and product risk, process complexity, contamination risk, previous findings, adverse trends, significant changes and the time elapsed since the last inspection.
High-risk or poorly performing systems may require more frequent review. Stable, well-controlled systems may be inspected less frequently, provided the interval remains justified and consistent with applicable requirements and the approved procedure.
2. Define the scope and objective
Every inspection should begin with a clear scope. A vague instruction such as “inspect production” is difficult to execute consistently. A stronger scope would be:
Evaluate dispensing and granulation controls for non-sterile oral solid dosage products, including material identification, line clearance, status labelling, environmental conditions, equipment cleaning and batch-documentation practices.
The inspection plan should identify:
- The area, process or system being inspected
- The objective and applicable products or operations
- The inspection date, duration and team
- The reference standards and procedures
- The records or activities to be sampled
- Any exclusions from the scope
The scope should be large enough to reveal system performance, but focused enough to permit detailed examination.
3. Select competent and sufficiently independent inspectors
The team should understand both GMP principles and the operation being examined. Useful competencies include knowledge of applicable requirements, interviewing and observation skills, record and electronic-data review, risk assessment, investigation and clear report writing.
Independence does not always require an external consultant. It means inspectors should be sufficiently removed from direct responsibility for the activity to evaluate it objectively. A production manager, for example, should not be the sole inspector of the production system they manage.
Technical specialists can assist with engineering, validation, microbiology or computerized systems. Responsibility for the final conclusions should remain clearly assigned.
4. Prepare before entering the area
Good preparation prevents the inspection from becoming an unfocused facility tour. Review relevant information in advance, including:
- Previous internal and regulatory inspection reports
- Previous CAPA status and effectiveness
- Recent deviations, OOS and OOT results
- Complaints, returns, recalls and rejected or reprocessed batches
- Change controls and product quality reviews
- Environmental, utility and process-performance trends
- Validation, qualification, calibration and maintenance status
- Training and competence assessments
- Data-integrity, supplier and contractor concerns
5. Begin with a concise opening meeting
Confirm the purpose, scope, team, timing, departmental contacts, likely documents, urgent escalation route and proposed closing meeting. The tone should be professional and fact-finding. Employees should understand that the objective is to evaluate systems and reduce risk—not to assign personal blame.
6. Inspect by observing, asking and verifying
Observe
Watch the work where it occurs. Look at personnel and material flows, gowning, line clearance, equipment status, segregation, storage, housekeeping, contemporaneous recording, label control and the handling of rejected or obsolete materials.
Ask
Use open questions. Instead of asking whether an employee has been trained, ask them to explain the activity and what they would do if a result fell outside its limit. Useful questions include:
- How do you know this is the current procedure?
- What evidence must be recorded before proceeding?
- What would cause you to stop the operation?
- How is an error corrected in this record?
- Who must be informed when this condition occurs?
- Where is the acceptance criterion defined?
Verify
Support statements with objective evidence. If an employee says that equipment is calibrated, examine its status and calibration record. If a supervisor says deviations are closed on time, sample the deviation register and investigation files. Reliable conclusions normally come from more than one source of evidence.
7. Follow processes across departmental boundaries
Serious failures often occur at interfaces between departments. Trace selected activities from beginning to end. A material can be followed through receipt, quarantine, sampling, testing, release, dispensing, reconciliation and return or disposal.
A batch can similarly be traced through material issuance, manufacturing, in-process control, packaging, laboratory testing, record review and final release. This approach can reveal gaps that a department-by-department checklist may miss.
8. Record objective evidence
Inspection notes should distinguish verified facts from assumptions. “Documentation practices are poor” is too vague. A stronger finding identifies what was sampled, what was observed and which requirement was not met.
In three of ten sampled equipment-use log entries dated 14–18 September, the operator recorded the activity but did not enter the completion time required by the approved procedure. The entries were reviewed and signed without the omission being detected.
Record document numbers, equipment identifiers, batch numbers, dates and other traceable details while respecting confidential information.
9. Evaluate significance—not just the number of findings
Findings should be assessed according to potential impact and the site’s approved classification procedure. Terminology differs among companies and regulators, but classifications commonly include:
Critical
A deficiency that has produced—or presents a significant risk of producing—a product harmful to patients, or involves serious misconduct, falsification or loss of essential control.
Major
A significant departure from GMP that may affect product quality, demonstrates failure of an important control or shows that an effective system has not been adequately implemented.
Other or minor
A deficiency below the threshold for critical or major classification that nevertheless requires correction to maintain an effective system.
Consider actual and potential product impact, patient risk, detectability, duration, frequency, affected products or batches, recurrence, other controls and data-integrity implications. Classification must follow the applicable regulatory framework and the approved SOP.
10. Escalate immediate risks without waiting for the report
Communicate immediate risks to product quality, patient safety, data integrity or employee safety through the site’s escalation process. Interim actions may include stopping an activity, segregating materials, placing batches on hold, preserving records, opening an investigation and assessing previously manufactured batches.
11. Conduct a factual closing meeting
Present the main observations and confirm factual details. The inspected department should be able to correct misunderstandings, provide unavailable evidence, clarify the affected scope and explain immediate containment. The meeting should not become a negotiation to remove valid findings.
12. Write a clear and actionable report
The report should include:
- Inspection title, date, scope and team
- Departments, activities, documents and records examined
- Positive practices where useful
- Findings supported by objective evidence
- Applicable requirements or procedural references
- Risk classification and immediate action taken
- Required response, due date, distribution and approval
Each finding should describe one coherent issue. The report should be understandable to someone who did not attend the inspection.
13. Convert findings into effective CAPA
Closing the inspection report is not the same as resolving the underlying risks. Each significant finding should proceed through an appropriate CAPA process.
Correction
Address the specific observed condition—for example, an overdue calibration, damaged status label or missed procedural step.
Root-cause investigation
Determine why the failure occurred. Retraining should not automatically be accepted as the cause. Consider procedure and process design, workload, staffing, competence, equipment, supervision, materials, environment and organisational factors.
Corrective and systemic action
Remove or control the identified cause and determine whether the same weakness could exist in other processes, products, departments or sites.
Effectiveness verification
Require evidence that the actions achieved their intended result. This may involve reviewing subsequent batches, repeating an inspection, demonstrating competence, analysing recurring deviations or confirming sustained compliance over a defined period.
An action should not be considered effective merely because it was completed on time.
The CAPA effectiveness-check guide explains how to set outcome-based criteria and make a documented closure decision.
For a structured approach to event description, evidence review and cause testing, read the practical deviation-investigation guide.
14. Trend the results
Individual findings show where a problem was observed. Trending shows what the organisation repeatedly fails to control. Useful measures include findings by system, critical and major findings, recurring observations, overdue CAPAs, closure time, effectiveness-check failures and completion against the approved inspection plan.
A declining number of findings does not automatically demonstrate improvement. It may indicate reduced inspection depth, narrow sampling or weak reporting. Metrics require interpretation.
A practical example
During an inspection, a cleaned blender carries an approved “clean” label and the equipment log confirms that cleaning was recorded. At first sight, the control appears satisfactory. Further review reveals:
- The cleaning procedure requires verification of a difficult-to-access discharge component.
- The checklist has no field confirming that this component was examined.
- Two operators describe different verification practices.
- The supervisor’s review only confirms that signatures are present.
- A similar issue was mentioned in a deviation six months earlier.
The problem is not simply an incomplete checklist or training gap. It may involve procedure design, inconsistent practice, weak supervisory review and ineffective learning from previous events.
An effective response would assess product impact, inspect relevant equipment, determine the root cause, revise the control where justified, verify competence and confirm effectiveness through subsequent observations. That is the difference between identifying a symptom and evaluating the system.
Common self-inspection mistakes
- Inspecting only before a regulatory visit
- Treating the checklist as proof of compliance
- Allowing departments to inspect their own work without adequate independence
- Reviewing procedures without observing actual practice
- Accepting verbal explanations without supporting evidence
- Sampling only conveniently available or “good” records
- Writing vague observations without traceable evidence
- Classifying findings without considering patient and product risk
- Using retraining as the default CAPA
- Closing actions without verifying effectiveness
- Failing to assess whether the issue exists elsewhere
- Measuring success only by the number of findings
The practical self-inspection sequence
- Select the area using the approved risk-based programme.
- Define the scope, objective and criteria.
- Appoint competent and sufficiently independent inspectors.
- Review previous findings, trends and relevant quality data.
- Prepare a focused inspection plan and sampling strategy.
- Observe operations, interview personnel and verify records.
- Document objective evidence and assess immediate risks.
- Conduct the closing meeting and issue the report.
- Investigate causes and implement proportionate CAPAs.
- Verify effectiveness, trend results and report systemic issues to management.
A successful self-inspection is not one that produces no findings. It is one that identifies meaningful weaknesses early, supports honest discussion and results in controls that work more reliably afterwards.
The objective is not to create the appearance of compliance. It is to determine whether the pharmaceutical quality system can consistently protect the product and the patient—even when no inspector is present.
Primary references
Accessed 21 September 2026. Always verify the current version and requirements applicable to your jurisdiction, products and approved quality system.
Educational notice: This article provides general educational information. Manufacturers should apply their approved procedures, product and process knowledge, quality-risk-management principles, marketing-authorisation commitments and the requirements of their applicable regulatory authorities.